EQL PHARMA AB (7JK) — Net Asset Quality Index
EQL PHARMA AB (7JK) has a Net Asset Quality Index of 31.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €850.89 Million minus total liabilities of €583.83 Million yields net assets of €267.06 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read 7JK total debt and obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
EQL PHARMA AB Net Asset Quality Index Over Time (2022–2026)
This chart shows how EQL PHARMA AB's Net Asset Quality Index has evolved across 5 annual periods from 2022 to 2026. As of March 2026, the index stands at 31.4%, representing net assets of €267.06 Million against total assets of €850.89 Million EUR. For live market cap and overall valuation, see 7JK company net worth.
Annual Net Asset Quality Index for EQL PHARMA AB (2022–2026)
The table below presents the year-by-year Net Asset Quality Index for EQL PHARMA AB from 2022 to 2026, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See EQL PHARMA AB (7JK) net assets for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2026 | 31.4% | €267.06 Million | €850.89 Million | €583.83 Million | ▲ +4.1 pp |
| 2025 | 27.3% | €221.03 Million | €808.82 Million | €587.79 Million | ▼ -20.2 pp |
| 2024 | 47.6% | €177.73 Million | €373.76 Million | €196.03 Million | ▼ -6.6 pp |
| 2023 | 54.2% | €154.75 Million | €285.70 Million | €130.94 Million | ▲ +2.2 pp |
| 2022 | 52.0% | €123.63 Million | €237.89 Million | €114.26 Million | — |